| 110.64 -5.51 (-4.74%) | 10-14 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 141.57 | 1-year : | 165.35 |
| Resists | First : | 121.2 | Second : | 141.57 |
| Pivot price | 99.96  |
|||
| Supports | First : | 84.66 |
Second : | 62.06 |
| MAs | MA(5) : | 109.82 |
MA(20) : | 92.65 |
| MA(100) : | 58.86 |
MA(250) : | 35.53 |
|
| MACD | MACD : | 11.3 |
Signal : | 9.8 |
| %K %D | K(14,3) : | 83.4 |
D(3) : | 87.3 |
| RSI | RSI(14): 69.8 |
|||
| 52-week | High : | 121.2 | Low : | 10.14 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ CDTX ] has closed below upper band by 20.1%. Bollinger Bands are 89.6% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 14 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 116.22 - 116.81 | 116.81 - 117.27 |
| Low: | 108.66 - 109.27 | 109.27 - 109.73 |
| Close: | 109.69 - 110.7 | 110.7 - 111.47 |
Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also advances its Cloudbreak platform to develop conjugates for the prevention and treatment of influenza and other viral infections, such as RSV, HIV, and the SARS-CoV-2 strains causing COVID-19. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. Cidara Therapeutics, Inc. was incorporated in 2012 and is based in San Diego, California.
Mon, 13 Oct 2025
Cidara Therapeutics to Present Late-Breaking Phase 2 Data on CD388 for Influenza at ID Week 2025 - Quiver Quantitative
Mon, 13 Oct 2025
Cidara Therapeutics to Present Late-Breaking Clinical Phase 2 Data on CD388 at ID Week 2025 - Stock Titan
Sat, 11 Oct 2025
Cidara Therapeutics (NASDAQ:CDTX) Shares Gap Up on Analyst Upgrade - MarketBeat
Fri, 10 Oct 2025
Cidara Therapeutics (CDTX) Is Up 10.8% After FDA Grants Breakthrough Therapy Designation to CD388 - Sahm
Fri, 10 Oct 2025
CDTX Stock Up on FDA's Breakthrough Therapy Tag for CD388 in Influenza - The Globe and Mail
Fri, 10 Oct 2025
Cidara Therapeutics Surges Ahead of ESWI 2025 Presentation and JP Morgan Coverage - Benzinga
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 25 (M) |
| Shares Float | 19 (M) |
| Held by Insiders | 0.8 (%) |
| Held by Institutions | 107.3 (%) |
| Shares Short | 3,050 (K) |
| Shares Short P.Month | 2,150 (K) |
| EPS | -7.64 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 21.56 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -23.7 % |
| Return on Equity (ttm) | -37.1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -4.29 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -5.27 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -129 (M) |
| Levered Free Cash Flow | -101 (M) |
| PE Ratio | -14.51 |
| PEG Ratio | 0 |
| Price to Book value | 5.12 |
| Price to Sales | 0 |
| Price to Cash Flow | -21.75 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|